Beta
Fluvastatin
medication Under reviewA statin medication used to lower cholesterol levels and reduce the risk of cardiovascular disease.
Research summary
Research on fluvastatin in humans is extensive for dyslipidemia and cardiovascular risk reduction, but the vast majority of trials involve patients with hypercholesterolemia, metabolic disease, or established cardiovascular disease rather than completely healthy, normolipidemic volunteers. In these patient populations, randomized controlled trials and long-term outcome studies show that fluvastatin significantly reduces LDL cholesterol and slows the progression of coronary atherosclerosis, with modest evidence for reducing the need for coronary revascularization procedures and certain cardiac events. Data specifically in healthy human volunteers are largely limited to pharmacokinetic and bioequivalence studies, which demonstrate predictable absorption and metabolism and a tolerable safety profile at standard doses. Adverse effects in these settings are usually mild and include headache and gastrointestinal symptoms, with rare but important risks of liver enzyme elevation and muscle-related complications at a class level. Overall, the consensus is that fluvastatin is an effective statin for lipid lowering with a safety profile comparable to other agents in its class when used at recommended doses under medical supervision.
Reported Benefits
No reports yet
Be the first to report this effect and help the community.
Add Fluvastatin to your stack to report effects
Pharmacokinetics and safety of fluvastatin sodium extended-release tablets in healthy subjects
Novartis Research Group
Fluvastatin for secondary prevention of cardiac events in patients with coronary heart disease (LCAS study)
LCAS Investigators
No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study.
ALERT Study Group
No reports yet
Be the first to report this effect and help the community.
Add Fluvastatin to your stack to report effects
Fluvastatin for secondary prevention of cardiac events in patients with coronary heart disease (LCAS study)
LCAS Investigators
No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study.
ALERT Study Group
No reports yet
Be the first to report this effect and help the community.
Add Fluvastatin to your stack to report effects
Fluvastatin for secondary prevention of cardiac events in patients with coronary heart disease (LCAS study)
LCAS Investigators
Reported Side Effects
No reports yet
Be the first to report this effect and help the community.
Add Fluvastatin to your stack to report effects
Pharmacokinetics and safety of fluvastatin sodium extended-release tablets in healthy subjects
Novartis Research Group
No reports yet
Be the first to report this effect and help the community.
Add Fluvastatin to your stack to report effects
Pharmacokinetics and safety of fluvastatin sodium extended-release tablets in healthy subjects
Novartis Research Group
No reports yet
Be the first to report this effect and help the community.
Add Fluvastatin to your stack to report effects
Safety profile of fluvastatin in clinical trials: incidence of liver enzyme elevations and muscle-related events
Worldwide fluvastatin clinical trial program
No reports yet
Be the first to report this effect and help the community.
Add Fluvastatin to your stack to report effects
Safety profile of fluvastatin in clinical trials: incidence of liver enzyme elevations and muscle-related events
Worldwide fluvastatin clinical trial program
Related health conditions
Research showing how this habit affects specific health conditions. Always consult healthcare professionals.
May Help With
Coronary artery disease or other cardiac conditions
Fluvastatin for secondary prevention of cardiac events in patients with coronary heart disease (LCAS study)
LCAS Investigators
No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study.
ALERT Study Group
Elevated LDL cholesterol or total cholesterol levels
Safety profile of fluvastatin in clinical trials: incidence of liver enzyme elevations and muscle-related events
Worldwide fluvastatin clinical trial program
Fluvastatin for secondary prevention of cardiac events in patients with coronary heart disease (LCAS study)
LCAS Investigators
Research (4 studies)
No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study.
ALERT Study Group
Safety profile of fluvastatin in clinical trials: incidence of liver enzyme elevations and muscle-related events
Worldwide fluvastatin clinical trial program
Pharmacokinetics and safety of fluvastatin sodium extended-release tablets in healthy subjects
Novartis Research Group
Fluvastatin for secondary prevention of cardiac events in patients with coronary heart disease (LCAS study)
LCAS Investigators
Community updates
No updates yet for this supplement.
Be the first to share your experience!